Relay Therapeutics shared updates at the Wells Fargo Healthcare Conference highlighting progress in vascular anomalies and breast cancer programs. The company strengthened its financial position and plans to start a Phase III frontline breast cancer trial early next year, with regulatory interactions expected before year-end. Their vascular anomalies program is advancing rapidly, supporting their transition toward becoming a commercial company. These developments mark a significant growth phase for Relay in the coming year.
RH is set to report Q2 2026 earnings facing challenges from a weak housing market and international expansion expenses. Analysts expect earnings per share to fall significantly to between $0.38 and $0.46, down from $2.93 last year, despite a slight r...
Chewy reported Q2 results largely in line with expectations, with net sales up 7.3% to $3.33 billion and adjusted earnings matching forecasts at $0.36 per share. However, shares fell 10.8% due to concerns about slowing organic growth, cautious consum...
Macy's reported Q1 earnings per share of $0.40, exceeding the $0.37 estimate, with revenue of $4.87 billion beating expectations. Growth was driven by strong sales in Bloomingdale's, Bluemercury, and Macy's stores. The company raised its full-year ne...
Tyson Foods faces operational challenges, especially in its beef segment, leading Piper Sandler to cut its price target from $78 to $66. The company lowered its 2026 revenue growth forecast to 1.5%-2% and expects a beef segment operating loss between...
Descartes Systems Group is set to release its Q2 2027 earnings with analysts expecting $0.57 EPS and $197.54 million revenue. The company recently acquired Extensiv for $120 million, enhancing its warehouse and fulfillment solutions for e-commerce an...
